New PET scan could help match liver transplants to right patients

NCT ID NCT04792801

Ongoing Diagnosis Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study looks at whether a special PET scan using two tracers (FDG and Choline) can improve how doctors decide which liver cancer patients should get a liver transplant. The trial involves 108 patients from two hospitals in France. The goal is to see if this scan catches cancer spread that standard tests miss, helping to avoid unnecessary transplants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PET CT with FDG and Choline tracers (diagnostic imaging procedure)
What this could lead to: If successful, this imaging method could help doctors more accurately decide which liver cancer patients are best suited for a transplant, potentially improving outcomes and organ use.
What could go wrong: This is a small, early-stage study with 108 participants, so results may not apply broadly. The PET scans may not significantly improve decision-making over current standard imaging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA LIVER TRANSPLANT

Contacts and locations

Locations

CHU Rouen

Rouen, France
Hop Claude Huriez Chu Lille

Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.